Preconception, pregnancy, and postnatal use of GLP-1 receptor agonist-based therapies in women with type 1, type 2, or gestational diabetes: a systematic review, meta-analysis, and international expert consensus statement
Preconception, pregnancy, and postnatal use of GLP-1 receptor agonist-based therapies in women with type 1, type 2, or gestational diabetes: a systematic review, meta-analysis, and international expert consensus statement. // The Lancet Obstetrics, Gynaecology, & Women’s Health. – URL: https://www.sciencedirect.com/science/article/pii/S3050503826002669?dgcid=rss_sd_all
Preconception, pregnancy, and postnatal use of GLP-1 receptor agonist-based therapies in women with type 1, type 2, or gestational diabetes: a systematic review, meta-analysis, and international expert consensus statement. The Lancet Obstetrics, Gynaecology, & Women’s Health. https://www.sciencedirect.com/science/article/pii/S3050503826002669?dgcid=rss_sd_all
“Preconception, pregnancy, and postnatal use of GLP-1 receptor agonist-based therapies in women with type 1, type 2, or gestational diabetes: a systematic review, meta-analysis, and international expert consensus statement.” The Lancet Obstetrics, Gynaecology, & Women’s Health.
@article{article69464,
title = {Preconception, pregnancy, and postnatal use of GLP-1 receptor agonist-based therapies in women with type 1, type 2, or gestational diabetes: a systematic review, meta-analysis, and international expert consensus statement},
journal = {The Lancet Obstetrics, Gynaecology, \& Women’s Health},
url = {https://www.sciencedirect.com/science/article/pii/S3050503826002669?dgcid=rss_sd_all}
}